Related Experiment Video

Updated: Jun 27, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Recent advances in molecular biology of thyroid cancer and their clinical implications

Mingzhao Xing1

  • 1Department of Medicine and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. mxing1@jhmi.edu

Otolaryngologic Clinics of North America
|December 2, 2008
PubMed

Insights

Thyroid cancer, the most common endocrine cancer, requires new management strategies. Advances in understanding molecular pathways and gene methylation offer new diagnostic and therapeutic opportunities.

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Thyroid cancer is the most common endocrine malignancy.
  • Its incidence is rapidly rising, necessitating novel management strategies.
  • Understanding its molecular biology is crucial for developing new treatments.

Purpose of the Study:

  • To review recent advances in understanding thyroid cancer biology.
  • To highlight molecular alterations, pathway dysregulation, and gene methylation in thyroid cancer.
  • To explore opportunities for molecular-based diagnostic, prognostic, and therapeutic strategies.

Main Methods:

  • Literature review of recent advances in thyroid cancer research.
  • Focus on molecular alterations, signaling pathways (MAPK, PI3K/Akt), and gene methylation.
  • Analysis of their roles in thyroid tumorigenesis and pathogenesis.

Main Results:

  • Identified key molecular alterations contributing to loss of radioiodine avidity.
  • Elucidated the pathogenic role of MAPK and PI3K/Akt pathways and associated genetic changes.
  • Highlighted aberrant gene methylation in thyroid cancer development.

Conclusions:

  • Recent biological insights provide unprecedented opportunities for thyroid cancer management.
  • Molecular-based diagnostic and prognostic tools can be developed.
  • Novel therapeutic strategies targeting specific molecular pathways are feasible.

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Related Concept Videos

Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...